Core Viewpoint - Beijing Su Xin Technology Co., Ltd. has successfully completed several million yuan in pre-A and pre-A+ financing rounds, with funds primarily aimed at scaling production lines for its PET recycling technology [1][2] Company Overview - Su Xin Technology focuses on the biological recycling of waste high polymer materials, particularly PET polyester, utilizing enzyme methods [1] - The company was founded in June 2024 and has a team with extensive academic and industry experience, including a CTO with a strong research background and a CEO with over ten years of management experience [1][2] Market Context - Global plastic consumption is projected to exceed 500 million tons in 2024, with a significant portion becoming waste, highlighting the urgent need for effective recycling solutions [2] - The Chinese market, being the largest plastic producer, presents substantial growth opportunities for recycling companies [3] Investment Considerations - The company’s strategy includes focusing on large-scale production lines, as most competitors target smaller, niche markets [2][3] - The team’s diverse background combines scientific expertise with industrial experience, enhancing the company’s ability to commercialize its technology [3] Technological Advancements - Su Xin Technology has developed a comprehensive enzyme library capable of degrading various high polymer materials, achieving breakthroughs in enzyme stability and efficiency [5][6] - The use of AI in enzyme discovery and optimization has accelerated the development process, allowing for significant advancements in enzyme performance [5][6] Production Capacity and Cost Management - The company has successfully established a pilot production line capable of processing 1,000 tons annually and is currently building a larger line expected to produce 10,000 tons by the end of 2025 [10][12] - Cost projections indicate that the biological recycling method could match the costs of traditional chemical methods, with further reductions anticipated as production scales up [10][12] Market Strategy - Su Xin Technology plans to target major brand companies in the next three years, leveraging its environmentally friendly production methods to capture market share and benefit from ESG policies [12] - The company aims to achieve significant sales milestones, including a projected revenue exceeding 100 million yuan by 2026 following the launch of its large-scale production line [12]

9月12日至13日，EmTech China 2025全球新兴科技峰会暨"50家聪明公司"（TR50）在上海静安国际科创社区举办，来自全球学术界、产业界与投资界人 士，就前沿技术在产业化深水区的具体路径与挑战，提出了宝贵的洞察与思考。 本届峰会以"中国未来"为主题，荟萃了包括诺贝尔奖得主、多国科学院院士、前沿领域科学家、产业领袖与创新先锋在内的数十位全球顶尖大脑，共同 围绕前沿科技从概念突破迈向产业化落地的关键路径与未来图景，展开了以"全球合作新未来"为主题的深度对话。同时，新一届"50家聪明公司"评选结果正 式发布。这些企业的技术路径、战略选择与落地成果，将成为观察未来十年科技走向的重要样本。 开幕式上，上海市静安区委副书记、区长翟磊表示，静安区正在"五个中心"建设中坚定走好第一方阵，锻长板、扬优势、优布局、强功能，抢抓上海建 设国际科技创新中心新机遇，主动把握产业发展前沿动向，致力于为企业打造集区位优势、产业生态和政策服务为一体的创新发展环境，通过一系列创新举 措构建更高效的生态链接，做广大创新创业者最为坚定而长久的同行人，并对本次峰会的举办表达了期待。 现场，上海市静安区科技和经济委员会主任王志佳围绕" ...

Group 1 - The 2025 Pujiang Innovation Forum will be held in Shanghai from September 20 to 22, focusing on building an open and cooperative global technology community, featuring a record number of participants and events [1] - The forum will include 1 opening ceremony, 1 main forum, 30 thematic forums, and 5 significant activities, such as the InnoMatch Technology Transfer Conference and WeStart Venture Capital Conference [1] - Since its inception in 2008, the forum has invited over 550 guests from more than 45 countries and regions, with nearly 40% of participants coming from countries like Belarus, the USA, Germany, Switzerland, Denmark, and regions of Hong Kong, Macau, and Taiwan [1] Group 2 - The InnoMatch Technology Transfer Conference will globally release 10,000 technology demands, with over 20 billion yuan in corporate investment and 2,000 job postings, showcasing over 80 cutting-edge products and experience scenarios [2] - Over the past five years, the InnoMatch conference has released more than 21,000 technology demands and 35,000 national technology innovation talent job postings, with a total cooperation intention amount nearing 18 billion yuan [2] - Shanghai's role as a technology innovation hub has been strengthened, with the implementation of the "Explorer Plan" and the introduction of nine policy measures to support basic research [2] Group 3 - Shanghai's innovation ecosystem is continuously improving, with 39 pilot units for technology transfer reform since 2024, resulting in nearly 250 empowered achievements and a conversion amount of 2.39 billion yuan [3] - The city is focusing on key links in technology transfer, creating a systematic ecosystem that includes concept validation, high-quality incubation, venture capital funds, and technology management [3] - An average of 300 new technology companies are established daily in Shanghai, indicating a robust growth in the technology sector [3]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪器信息网讯 金秋九月，第二十一届北京分析测试学术报告会暨展览会（简称BCEIA2025）于2025年9月10日在北 京·中国国际展览中心（顺义馆）隆重开幕。 会议现场 开幕式 BCEIA 2025开幕式由中国分析测试协会副理事长兼秘书长张新荣教授担任主持人。 张新荣 中国分析测试协会副理事长兼秘书长、清华大学教授、北京市理化分析测试中心主任 大会主席江桂斌院士发表开幕致辞。 国际合作伙伴代表，日本分析仪器工业会的吉田秀人（Hideto Yoshida）先生致贺词。 为庆祝BCEIA创办40周年，本届大会特设"特别贡献奖"，以表彰为创立BCEIA并为其发展倾注心血的老一辈协会领导 者。杨化先生、王顺昌先生、闫成德先生、吴波尔女士、张渝英女士荣获这一崇高荣誉。颁奖仪式由中国分析测试协会 副理事长刘虎威教授主持，中国分析测试协会理事长江桂斌院士和中国分析测试协会副理事长刘买利院士为获奖人颁 奖。 刘虎威 中国分析测试协会副理事长、北京大学教授 江桂斌 中国科学院院士、中国分析测试协会理事长、中国科 ...

Core Insights - The company, based on quantum physics, integrates artificial intelligence and robotic automation technology to build a multi-modal AI model system for drug discovery, establishing a data-driven technology barrier [1] - The company has achieved significant revenue growth and is moving towards profitability, with a projected revenue of 2.66 billion yuan in 2024, a 53% year-on-year increase, and a net loss reduction to 15.2 billion yuan [2] - The company has established a strong technical barrier with over 6.5 million high-precision quantitative data points and 1.9PB of cloud data, along with more than 200 AI models [3] - The company is expanding its business model into new materials and other fields, with a significant order of 5.99 billion USD signed with DoveTree [4] - The company is rated "strongly recommended" due to its innovative drug discovery platform and expected revenue growth reaching 7.86 billion yuan by 2025 [5] Revenue and Profitability - In 2024, the company expects to generate 2.66 billion yuan in revenue, a 53% increase year-on-year, and a net loss of 15.2 billion yuan, showing a reduction in losses [2] - By the first half of 2025, the company has achieved profitability with a revenue of 5.17 billion yuan, a 404% year-on-year increase, and an adjusted net profit of 1.42 billion yuan [2] Technical Advantages - The company has accumulated over 6.5 million high-precision quantitative data points and 1.9PB of cloud data, with a monthly output of over 30,000 reaction data points [3] - The company possesses over 200 AI models, including globally leading algorithms such as the protein structure prediction algorithm XtalFold [3] - The company operates a state-of-the-art automated laboratory with over 200 robotic workstations and a 5000m² automated lab [3] Business Expansion and Collaborations - The company is pursuing a global development strategy, establishing a research and service network across the Americas, Europe, and Asia-Pacific [4] - The company has secured a pipeline cooperation order worth 5.99 billion USD with DoveTree, contributing positively to its performance [4] - The company is expanding its technology platform into new fields such as renewable energy, agriculture, and industrial materials [4] Future Outlook - The company is expected to achieve revenues of 7.86 billion yuan in 2025, with adjusted net profits projected to improve over the next few years [5] - The current stock price corresponds to a price-to-sales ratio of 53.44 for 2025, indicating potential for narrowing losses as scale effects materialize [5]

Investment Rating - The report gives a "Strong Buy" rating for the company [6][7]. Core Insights - The company leverages quantum physics, artificial intelligence, and automation to drive drug and material research, establishing a data-driven technological barrier and gaining recognition from multinational pharmaceutical companies [1][6]. - The company has shown significant revenue growth, with a projected revenue of 2.66 billion RMB in 2024, a 53% year-on-year increase, and a remarkable 404% growth in the first half of 2025 [6][20]. - The company has secured a pipeline cooperation order worth 5.99 billion USD with DoveTree, indicating strong commercial potential [6][20]. Summary by Sections Company Overview - The company was founded in 2015, focusing on drug discovery and material design using quantum physics and AI technologies [11][12]. - It has established long-term strategic partnerships with major pharmaceutical companies, including Pfizer [12][18]. Industry Development - The AI for Science sector is expected to grow significantly, with applications across various high-tech fields, including drug discovery and materials science [25][28]. - The global AI solutions market is projected to grow from 139.5 billion USD in 2022 to 1,414.2 billion USD by 2030, with a CAGR of 33.5% [31][32]. Main Business Analysis - The company’s core business includes AI-driven drug discovery and intelligent automation solutions, with a focus on small molecules and new materials [19][20]. - The revenue from drug discovery solutions is expected to grow significantly, with a 615% increase in the first half of 2025 compared to the previous year [6][20]. Financial Forecast - The company anticipates revenues of 7.86 billion RMB in 2025, 9.75 billion RMB in 2026, and 14.07 billion RMB in 2027, with adjusted net profits gradually improving [6][8].

Investment Rating - The investment rating for the company is "Buy" [6][12]. Core Views - The company has achieved rapid revenue growth, with a 25.99% year-on-year increase in H1 2025, reaching 15.781 billion yuan, and a net profit attributable to shareholders of -1.43 billion yuan, indicating a reduction in losses by 7.60% [1][6]. - In Q2 2025, the company reported a revenue of 8.770 billion yuan, a year-on-year increase of 23.93% and a quarter-on-quarter increase of 25.10%, with a net profit of 0.55 billion yuan [1][6]. - The company is deepening its software and hardware integration strategy, with significant growth in computing products and smart electronics, which generated 6.756 billion yuan in revenue, a 72.77% increase year-on-year, accounting for 42.81% of total revenue [2][3]. Summary by Sections Financial Performance - In H1 2025, the company achieved a revenue of 15.781 billion yuan, with a year-on-year growth of 25.99% and a net profit of -1.43 billion yuan, showing a reduction in losses [1][6]. - Q2 2025 saw a revenue of 8.770 billion yuan, with a year-on-year increase of 23.93% and a quarter-on-quarter increase of 25.10%, alongside a net profit of 0.55 billion yuan [1][6]. - The operating cash flow for Q2 was 1.358 billion yuan, reflecting a 173.92% increase quarter-on-quarter [1][6]. Strategic Developments - The company is enhancing its software and hardware integration strategy, with a focus on AI and intelligent products, establishing a comprehensive product brand matrix [2][3]. - The company is actively participating in the HarmonyOS ecosystem, supporting the development of numerous applications and solutions across various industries [3]. Future Projections - Revenue projections for the company are estimated at 36.541 billion yuan, 42.373 billion yuan, and 49.304 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to reach 3.84 billion yuan, 5.18 billion yuan, and 7.81 billion yuan in the same years [3][4].

Core Insights - The company achieved a revenue of 1.293 billion yuan in the first half of 2025, representing a year-on-year growth of 14.02% and a net profit of 76 million yuan, which is a significant increase of 906.32% year-on-year [1][2] Revenue Performance - The overall revenue growth in the first half of the year was in double digits, with overseas growth outpacing domestic growth. Domestic revenue reached 986 million yuan, up 10.43%, while overseas revenue was 307 million yuan, up 27.31% [2] - In Q2 alone, the company reported a revenue of 737 million yuan, reflecting a year-on-year increase of 7.69% [2] Business Segmentation - Revenue from the construction formwork business was 830 million yuan, growing by 10.70%, while the prefabricated building business generated 203 million yuan, with a growth of 1.52% [2] - The gross margin for the construction formwork business improved to 32.85%, an increase of 7.36 percentage points year-on-year, while the prefabricated building business saw a gross margin of 18.86%, up 3.90 percentage points [3] Profitability Metrics - The overall gross margin for the first half of 2025 was 28.66%, an increase of 4.22 percentage points year-on-year, with Q2 gross margin at 29.10%, up 2.88 percentage points [2][3] - The net profit margin for the first half was 5.89%, up 5.22 percentage points year-on-year, and the net profit margin after deducting non-recurring items was 5.39%, up 6.52 percentage points [3] Cash Flow and Financial Health - The company reported a net cash inflow from operating activities of 100 million yuan, marking a turnaround year-on-year, with a cash collection ratio of 98.88%, up 16.59 percentage points [4] - The asset-liability ratio decreased by 3.49 percentage points to 65.71%, and accounts receivable turnover days reduced by 12.95 days to 209.77 days [4] Strategic Developments - The company is making progress in its new materials business, having formed a strategic partnership with Hefei Microcosm Era Digital Technology Co., Ltd. to establish a joint venture focused on quantum technology applications [4] - The company hosted a new materials launch event in August, showcasing innovative materials and inviting international clients to strengthen future collaborations [4] Future Outlook - The company is at a turning point in its main business, with explosive growth in overseas markets and a gradual recovery in the domestic market. The new materials research and development initiatives are expected to significantly contribute to revenue as results are commercialized [5] - The performance targets set in the previous equity incentive plan aim for net profits of 80 million, 200 million, and 300 million yuan for the years 2024-2026, with overseas revenue targets of no less than 500 million, 1 billion, and 1.5 billion yuan [5]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company achieved significant growth in the first half of 2025, with operating revenue reaching 1.293 billion yuan, a year-on-year increase of 14.02%. The net profit attributable to shareholders was 76 million yuan, reflecting a remarkable year-on-year growth of 906.32% [2][4]. - The overall revenue growth was driven by differentiated performance across business segments, with the construction formwork business generating 830 million yuan (up 10.70%) and the prefabricated building business generating 203 million yuan (up 1.52%). International revenue outpaced domestic growth, with a 27.31% increase [8]. - The company's gross margin improved significantly, with a comprehensive gross margin of 28.66%, up 4.22 percentage points year-on-year. The net profit margin also saw a substantial increase, reaching 5.89%, up 5.22 percentage points year-on-year [8]. - The company reported a positive operating cash flow of 100 million yuan in the first half of 2025, with a cash collection ratio of 98.88%, an increase of 16.59 percentage points year-on-year [8]. - The company is making progress in its new materials business, establishing a joint venture to accelerate the commercialization of quantum technology and collaborating with academic institutions to enhance material performance [8]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.293 billion yuan, a 14.02% increase year-on-year. The net profit attributable to shareholders was 76 million yuan, a 906.32% increase year-on-year, with a non-recurring net profit of 70 million yuan, turning positive year-on-year [2][4]. - The gross margin for the first half of 2025 was 28.66%, up 4.22 percentage points year-on-year, while the net profit margin was 5.89%, up 5.22 percentage points year-on-year [8]. Business Segments - The construction formwork business generated 830 million yuan, a 10.70% increase, while the prefabricated building business generated 203 million yuan, a 1.52% increase. Domestic revenue was 986 million yuan (up 10.43%), and international revenue was 307 million yuan (up 27.31%) [8]. Cash Flow and Financial Health - The company reported a positive operating cash flow of 100 million yuan, with a cash collection ratio of 98.88%, up 16.59 percentage points year-on-year. The asset-liability ratio decreased by 3.49 percentage points to 65.71% [8]. Strategic Developments - The company is advancing its new materials business, having formed a strategic partnership to establish a joint venture focused on quantum technology and collaborating with universities to enhance research and development efficiency [8].

深势科技是全球AI for Science开拓者，依托在交叉学科领域的深耕，构建了"深势·宇知"AI for Science大 模型体系，并进一步解决科学研究和工业研发领域的关键问题，将众多学科的科研方法从"实验试错 / 计算机"时代带入了"预训练模型时代"。 为攻克这些技术难点，深势科技与火山引擎数智平台深度合作，融合火山引擎DataSail数据集成工具、 AI数据湖服务LAS及火山方舟模型服务的核心能力。 在数据处理流程上，LAS的可视化操作界面提升了开发效率，技术团队得以将更多资源投入核心算法研 发。通过数据清洗预处理与火山方舟模型服务的协同作用，整体翻译准确率提升约5%。在图片处理方 面，调用大模型判断图片所属科学领域及关注内容，调用图片理解模型生成向量并回写，图片处理的效 率及准确率也有所提升。 面向高峰业务场景，火山引擎提供了充沛的算力支持，通过按需调整的流量配额，保障了大流量下的系 统稳定性。统一高效的数据处理体系，成功为海量科研信息架设起一条无缝流转的"信息动脉"。 当前，越来越多科研人员采用深势科技的产品实现海量文献的高效检索、管理与阅读，并利用平台专业 工具提升科研效率。未来，火山引擎还将 ...